Wall Street expects a year-over-year increase in earnings on higher revenues when Amicus Therapeutics (FOLD) reports results for the quarter ended December 2024. While this widely-known consensus ...

Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD – Get Free Report) have received an average recommendation of “Moderate Buy” from the nine brokerages that are covering the company, MarketBeat reports ...

PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development programs will be included at ...

Life sciences trade association BioNJ has announced the election of its 2025 Officers and Board Members in concert with BioNJ ...

In a report released today, Ritu Baral from TD Cowen maintained a Buy rating on Amicus (FOLD – Research Report), with a price target of $20.00.

Amicus Therapeutics, Inc. PRINCETON, N.J., Feb. 03, 2025 (GLOBE NEWSWIRE) -- Amicus Therapeutics (Nasdaq: FOLD), today announced that two oral presentations and 20 posters across its development ...